BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved the survival of patients with peritoneal surface malignancy. On recurrence, a repeat CRS/HIPEC is a treatment option. STUDY DESIGN: A retrospective analysis of 868 CRS/HIPEC procedures was performed. Type of primary, functional status, completion of resection, hospitalization, morbidity, mortality, and survival were reviewed.
Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC), is a treatment option for peritoneal carcinomatosis (PC). This treatment modality has resulted in long-term survival for selected patients with peritoneal surface malignancies. [1] [2] [3] The principle underlying this therapeutic modality is the initial surgical resection of all macroscopic peritoneal disease, and subsequently treating any residual, microscopic peritoneal disease with hyperthermic chemotherapy. Intraperitoneal chemotherapy provides a higher local concentration of the chemotherapeutic agents than can be achieved with even the most aggressive dosing, and the addition of hyperthermia results in a potentiation of cytotoxicity. Reported 5-year survival rates for pseudomyxoma, PC of a colorectal origin, and peritoneal mesothelioma range from 60% to 80%, 25% to 51%, and 29% to 63%, respectively. [3] [4] [5] Unfortunately, peritoneal recurrence is noted in a substantial number of these patients within 3 years after CRS/ HIPEC. Approximately 80% for patients with PC of a colorectal origin, 40% for patients with mesothelioma, and 25% to 44% for patients with pseudomyxoma. [6] [7] [8] The primary goal of this article is to evaluate the utility of a repeat CRS/HIPEC by recording the procedure's spe-cific morbidity and mortality. The secondary goal is to describe the impact of the procedure to overall survival.
METHODS
This is a retrospective analysis of a prospectively maintained database of 868 CRS/HIPEC procedures.
Patient data relevant to our analysis included age, race, sex, Eastern Cooperative Oncology Group (ECOG) graded functional status, date of initial and repeat CRS/ HIPEC, chemoperfusion agent, R status of resection, type of malignancy, hospital and ICU stay, morbidity, mortality and median survival. Eligibility criteria for initial CRS/ HIPEC were ECOG Յ3, histologic or cytologic diagnosis of PC, and complete recovery from earlier systemic chemotherapy or radiation treatments, resectable or resected primary lesion, debulkable peritoneal disease, no extraabdominal disease, and limited medical comorbidities. Patients were considered for second CRS HIPEC if they had an initial R0, R1, or R2a resection, had a complete recovery from earlier systemic chemotherapy or radiation treatments, were ECOG 0, 1, or 2, had disease considered to be resectable based on imaging, and had no extraabdominal disease. Selected patients with R2b and R2c were considered for second procedures if all disease near bowel and bile ducts was considered resectable. All patients had a complete history and physical, tumor markers and CT of the chest, abdomen, and pelvis before all HIPEC procedures. The CRS/HIPEC procedure was conducted as previously described by our group. 9 IRB approval was obtained for this study.
Statistical analyses
Descriptive statistics, including frequencies and proportions for categorical data, and means and standard deviations for continuous outcomes were calculated for all study measures. To assess for differences between study groups, Fisher's exact tests were used as it is more efficient than a chi-square test when cell counts are small. These tests give the exact p value, rather than an approximation, of the observed cell frequencies. A p value Ͻ0.05 was considered to be statistically significant. Survival estimates were calculated using the Kaplan-Meier method; to compare groups, the log-rank test of the chi-square approximation was used. To assess which factors were significant in a multivariate model, proportional hazards regression was used. Statistical analyses were performed using SPSS 19 (SPSS, Inc) and SAS 9.2 (SAS Institute) software.
RESULTS
From 1993 to 2010, sixty-six repeat CRS/HIPEC procedures for isolated peritoneal tumor recurrence were performed in 62 patients in our institution. Mean age of patients was 46.4 Ϯ 11 years. These 62 patients represent a highly selected subset (7.7%) from 868 patients who underwent a CRS/HIPEC procedure.
The origin of the primary tumors was appendiceal in 33 (53.2%), colorectal cancer in 4 (6.5%), malignant mesothelioma in 7 (11.3%), gallbladder cancer in 1 (1.6%), gastric cancer in 2 (3.2%), gastrointestinal stromal tumors in 2 (3.2%), ovarian in 8 (12.9%), sarcoma in 2 (3.2%), small bowel in 2 (3.2%), and urachal in 1 (1.6%) ( Table 1) .
Mean interval between the initial CRS/HIPEC and the diagnosis of peritoneal recurrences was 27.0 Ϯ 29.0 months; median estimate was 17.0 months, with a range of 4.1 to 143.0 months.
Resection status after repeat CRS/HIPEC
Of the 27 patients who had an R0ϪR1 resection during their first CRS/HIPEC, 16 (59.3%) had an R0ϪR1 resection during the repeat CRS/HIPEC, 6 (22.2%) had an R2a resection, and 5 (18.7%) had an R2bϪR2c resection status. Of the 25 patients who had an R2a resection during their first CRS/HIPEC, 9 (36%) had an R0ϪR1 resection during the repeat CRS/HIPEC, 9 (36%) had an R2a resection, and 7 (18.7%) had an R2bϪR2c resection status. Of the 10 patients who had an R2bϪR2c resection during their first CRS/ HIPEC, 2 (20%) had an R0ϪR1 resection during the repeat CRS/HIPEC, 1 (10%) had an R2a resection, and 7 (70%) had an R2bϪR2c resection status (Table 1) .
Postoperative morbidity and mortality and duration of hospitalization
The 30-day postoperative mortality rate was 3.2% (2 patients). The postoperative morbidity rate was 43.5% (27 patients). Of these 27 patients, 18 (66.7%) suffered a Clavien-Dindo grade I/II complication, and 9 (33.3%) suffered a Clavien-Dindo grade III/IV complication 10 (Table 2). Median hospital stay was 7.5 days (range 4 to 49 days). Mean duration of postoperative hospitalization on the surgical floor was similar after the first and second cytoreduction (7 vs 7.5 days) with the repeat CRS/HIPEC patients requiring less ICU time (1.5 vs 1 day).
Survival and prognostic factors
Median follow-up was 60.8 months after the second CRS/ HIPEC (range 1 to 111 months). The median overall sur- (Table 3) . On multivariate analysis, the R resection status after the second CRS/HIPEC (p ϭ 0.013) along with the time interval between the 2 cytoreductions (p ϭ 0.009), was statistically significant in predicting improved survival. On the contrary, the R resection status after the first cytoreduction and the type of primary malignancy were not significant in predicting overall survival (Table 4) .
DISCUSSION
Peritoneal carcinomatosis can no longer be considered as the absolute synonym to unresectable, terminal metastatic disease. Clearly, a subset of PC patients will present with disease confined to the peritoneal cavity. For this specific group of patients, CRS/HIPEC has emerged as a procedure that, in specialized high-volume centers, can provide a substantial increase in overall survival, with reasonably good quality of life. 11, 12 This procedure includes resection of involved organs and stripping of infiltrated peritoneum, followed by heated intraperitoneal chemotherapy. It is a major procedure with considerable morbidity and mortality. 13 A prospective randomized trial performed on patients with PC from principally colorectal primary reported an astonishing 45% 5-year survival when a complete cytoreduction was achieved.
14 Therefore, some of these patients live long enough to present with recurrence or progression of disease that is refractory to chemotherapy. At this point, they can be evaluated for a possible second CRS/HIPEC. Until now, there has been reasonable skepticism about the tolerability of a repeat cytoreduction due to the extent of the operation, and the physiologic impact on a patient already compromised by an advanced stage of disease. 15 Our earlier accumulated experience with initial CRS/ HIPEC has demonstrated that long-term survival was ad- versely influenced by increased volume of disease, R2 status of resection, high ECOG, poor nutrition, and high grade of the primary tumor. 16 The patients we considered to be the best candidates for a successful repeat cytoreduction are those who maintain an ECOG 0Ϫ1 functional status, had an earlier R0 or R1 resection, were maintaining their nutritional reserves (albumin Ͼ3 g/dL), had a low-grade tumor without nodal metastatic disease, and had an interval between the 2 procedures that was at least 1 year long. These selection criteria are mirrored by the median interval of 27 months between the 2 procedures. For those patients who had an earlier R2 resection, the option of a second cytoreduction was considered only in patients with a prolonged progression-free interval (notably more than a year), as the patient was maintaining his functional and nutritional status. These selection criteria were guidelines, and a handful of patients not meeting criteria underwent a second procedure. Interesting enough, almost 1 of 5 or 18% (11 of 62) of the second cytoreduction patients had an ECOG status at least 2 and 20% (2 of 10) of the patients who initially were left with macroscopic disease after the first cytoreduction (R2 resection) had a complete second cytoreduction (R0/1 resection). This is important in peritoneal surface disease from a low-grade appendiceal primary where the completeness of the second cytoreduction and not the completeness of the first cytoreduction is the one that determines long-term survival. 17 The site of origin clearly impacts the outcomes after initial CRS/HIPEC. It is not surprising that favorable biological behavior, such as that encountered with low-grade appendiceal cancer (n ϭ 28), was associated with a prolongation of median survival of an additional 71.3 months (range 0.1 to 111.7 months). This resulted in a median survival of 108.5 months from the first cytoreduction. Colon cancer PC patients (n ϭ 4) had an mean of 55.7 months median survival after the second CRS/HIPEC that resulted in a median survival of 137.4 months after the first cytoreduction. Although highly selected, this result is vastly superior to any systemic chemotherapy, including oxaliplatin and irinotecan regimens. 18 Similarly, ovarian cancer PC patients (n ϭ 8) had a median of 53.9 and 60.1 months survival after second and first cytoreductions, respectively. Several of these patients continued to remain free of recurrent disease at time this article was written.
The morbidity of the procedure for the entire group of repeat CRS/HIPEC was 43.5% and this number includes both major and minor complications. The mortality was 3.2%, which is considerably less than the 6.5% mortality rate quoted to these patients when they present for their first cytoreduction. 13 The mean duration of the postoperative hospitalization, both in the ICU and on the surgical floor, was similar after the first and second cytoreductions, with the repeat CRS/HIPEC patients requiring 33% less ICU time. This morbidity and mortality is comparable with that experienced by our patients undergoing an initial CRS/HIPEC. On multivariate analysis, the R status of the second CRS/HIPEC (p ϭ 0.013), and the interval between the 2 procedures (p ϭ 0.009), were the only 2 significant factors in predicting improved survival, indicating the ultimate importance of the biological behavior of the tumor. Patients who had an R0/1 complete cytoreduction had a median survival of 55.7 months, which was considerably better than the 20.3 months of an R2 resection. This indicates that patients who will have prolonged survival regardless of the type of primary are those with anatomic distribution of disease that is as amenable to complete cytoreduction as those with favorable tumor biology. The importance of complete cytoreduction after a repeat HIPEC has also been demonstrated by Esquivel and Sugarbaker in peritoneal surface disease from appendiceal primary. 17 In that article, the interval between the 2 procedures was not prognostic of improved survival, possibly because the patient population included asymptomatic patients with normal imaging studies, and patients who went to the operating room for elective procedures, such as colostomy reversal or incisional hernia repair. 17 We recognize that the current article is limited in that it represents a retrospective review from a single institution where patients are selected based on clinical experience obtained during a 20-year period of time. Therefore, patient selection bias is inevitably part of the reported outcomes. Patients were selected based primarily on performance status and favorable biological behavior of the tumor. Despite this, however, our experience measures the surgical outcomes of the same procedure in a variety of primaries with different biological behavior and prognosis.
CONCLUSIONS
We do not claim that these results apply to every patient with peritoneal surface disease. On the contrary, selecting not only the correct patient but also the correct timing to perform the procedure is of paramount importance in achieving prolonged survival with meaningful quality of life. This is not an easy clinical decision, and the operation itself is definitely demanding for both the patient and surgeon. Considering the substantial learning curve for this operation, these patients should be referred to high-volume tertiary care centers with expertise in the treatment of peritoneal surface disease, where the procedure can be performed with at least the same morbidity and mortality as the first cytoreduction. 19 An incomplete (R2a,b) first cytoreduction is not an absolute contraindication to an attempted second cytoreduction. The type of primary is not significant as long as the clinical behavior of the disease is favorable. A repeat CRS/HIPEC should not be undertaken unless it can provide improved survival or can control symptomatic disease with quality of life. However, in selected patients, repeat CRS/HIPEC procedures can be associated with prolonged survival with the potential of disease-free survival. 
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